Skip to main content
Article thumbnail
Location of Repository

A Dialogue between the Hypoxia-Inducible Factor and the Tumor Microenvironment

By Frédéric Dayan, Nathalie M. Mazure, M. Christiane Brahimi-Horn and Jacques Pouysségur

Abstract

The hypoxia-inducible factor is the key protein responsible for the cellular adaptation to low oxygen tension. This transcription factor becomes activated as a result of a drop in the partial pressure of oxygen, to hypoxic levels below 5% oxygen, and targets a panel of genes involved in maintenance of oxygen homeostasis. Hypoxia is a common characteristic of the microenvironment of solid tumors and, through activation of the hypoxia-inducible factor, is at the center of the growth dynamics of tumor cells. Not only does the microenvironment impact on the hypoxia-inducible factor but this factor impacts on microenvironmental features, such as pH, nutrient availability, metabolism and the extracellular matrix. In this review we discuss the influence the tumor environment has on the hypoxia-inducible factor and outline the role of this factor as a modulator of the microenvironment and as a powerful actor in tumor remodeling. From a fundamental research point of view the hypoxia-inducible factor is at the center of a signaling pathway that must be deciphered to fully understand the dynamics of the tumor microenvironment. From a translational and pharmacological research point of view the hypoxia-inducible factor and its induced downstream gene products may provide information on patient prognosis and offer promising targets that open perspectives for novel “anti-microenvironment” directed therapies

Topics: Review Paper
Publisher: Springer Netherlands
OAI identifier: oai:pubmedcentral.nih.gov:2654353
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Citations

    1. A et al (2005) Glucose requirement for hypoxic accumulation of hypoxia-inducible factor-1alpha (HIF-1alpha).
    2. (2002). Acidic extracellular pH induces vascular endothelial growth factor (VEGF) in human glioblastoma cells via ERK1/2 MAPK signaling pathway: mechanism of low pH-induced VEGF.
    3. (2007). Aerobically derived lactate stimulates revascularization and tissue repair via redox mechanisms. Antioxid Redox Signal 9:1115–1124
    4. (2007). An endoplasmic reticulum transmembrane prolyl 4-hydroxylase is induced by hypoxia and acts on hypoxia-inducible factor alpha.
    5. (1997). Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis.
    6. (2005). Anoxia is necessary for tumor cell toxicity caused by a low-oxygen environment.
    7. Appelhoff RJ et al (2004) Genetic analysis of the role of the asparaginyl hydroxylase factor inhibiting hypoxia-inducible factor (HIF) in regulating HIF transcriptional target genes.
    8. (2006). ARDent about acetylation and deacetylation in hypoxia signalling.
    9. (2006). Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance.
    10. (2004). Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    11. Bishopric NH (2005) BNip3 and signal-specific programmed death in the heart.
    12. Bishopric NH et al (2002) Hypoxia and acidosis activate cardiac myocyte death through the
    13. Busco G et al (2007) The NHERF1 PDZ2 domain regulates PKA-RhoA-p38-mediated NHE1 activation and invasion in breast tumor cells.
    14. (2001). C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation.
    15. (2004). Catalytic properties of the asparaginyl hydroxylase (FIH) in the oxygen sensing pathway are distinct from those of its prolyl 4-hydroxylases.
    16. (2003). Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL.
    17. Chiang GG et al (2002) Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin.
    18. (2006). Does the tumor microenvironment influence radiation-induced apoptosis?
    19. (2005). Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNAbinding activity.
    20. (2005). Effect of desferrioxamine and metals on the hydroxylases in the oxygen sensing pathway.
    21. Feldser D et al (2000) Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics.
    22. (2002). FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor.
    23. (2000). Fractals and cancer.
    24. (2007). Functional antibodies produced by oncolytic clostridia.
    25. (2002). Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells.
    26. Gothie E et al (1999) p42/p44 mitogenactivated protein kinases phosphorylate hypoxia-inducible factor 1alpha (HIF-1alpha) and enhance the transcriptional activity of HIF-1.
    27. (2007). Harnessing the hypoxia-inducible factor in cancer and ischemic disease.
    28. (2004). HIF activation by pH-dependent nucleolar sequestration of VHL.
    29. (2006). HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption.
    30. (2007). HIF-1 regulates cytochrome oxidase subunits to optimize efficiency of respiration in hypoxic cells.
    31. (2004). HIF-1: master and commander of the hypoxic world. A pharmacological approach to its regulation by siRNAs.
    32. (2003). HIF-1alpha is essential for myeloid cell-mediated inflammation.
    33. HK et al (2006) Akt1 activation can augment hypoxia-inducible factor-1alpha expression by increasing protein translation through a mammalian target of rapamycin-independent pathway.
    34. Hurley RL et al (2004) Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex.
    35. (2001). Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumors in vivo.
    36. (2004). Hypoxia induces adhesion molecules on cancer cells: A missing link between Warburg effect and induction of selectin-ligand carbohydrates.
    37. (2003). Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene.
    38. (2007). Hypoxia signalling controls metabolic demand.
    39. (2006). Hypoxia signalling in cancer and approaches to enforce tumour regression.
    40. (2007). Hypoxia-induced Autophagy is mediated through the HIF-dependent induction of BNIP3 and BNIP3L.
    41. (2006). Hypoxia-inducible factor-1-dependent repression of E-cadherin in von Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B.
    42. (2002). Hypoxia-inducible factor-1alpha mRNA contains an internal ribosome entry site that allows efficient translation during normoxia and hypoxia.
    43. (2007). Hypoxia-inducible transcription factor-1 alpha determines sensitivity of endothelial cells to the proteosome inhibitor bortezomib.
    44. (2007). Hypoxia, drug therapy and toxicity.
    45. (2002). Hypoxiainducible factor (HIF) asparagine hydroxylase is identical to factor inhibiting HIF (FIH) and is related to the cupin structural family.
    46. (2006). Identification of MAPK phosphorylation sites and their role in the localization and activity of hypoxia-inducible factor-1alpha.
    47. (2005). Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2 alpha in von Hippel-Lindau renal cell carcinoma.
    48. (2007). Imaging oxygenation of human tumours.
    49. (2006). Inconsistent effects of acidosis on HIF-alpha protein and its target genes.
    50. (2002). Induction of hypoxia-inducible factor-1alpha by transcriptional and translational mechanisms.
    51. (2002). Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells.
    52. (2007). Is lactate food for neurons? Comparison of monocarboxylate transporter subtypes in brain and muscle.
    53. Knauth E et al (2003) Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy.
    54. (2004). Loss of HIF-1alpha in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis.
    55. (2006). Lysyl oxidase is essential for hypoxia-induced metastasis.
    56. (2006). Lysyl oxidase: an oxidative enzyme and effector of cell function. Cell Mol Life Sci 63:2304– The hypoxia-inducible factor 6774. Payne SL,
    57. (2006). Macrophages: obligate partners for tumor cell migration, invasion, and metastasis.
    58. (2003). MAPK signaling upregulates the activity of hypoxia-inducible factors by its effects on p300.
    59. (2006). Mature results from a randomized Phase II trial of cisplatin plus 5-fluorouracil and radiotherapy with or without tirapazamine in patients with resectable Stage IV head and neck squamous cell carcinomas.
    60. (2001). MCT1-mediated transport of L-lactic acid at the inner blood-retinal barrier: a possible route for delivery of monocarboxylic acid drugs to the retina.
    61. Mellinghoff IK et al (2006) Hypoxiainducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.
    62. (1994). Metabolic abnormalities and grade of encephalopathy in acute hepatic failure.
    63. (2004). Notch activation induces endothelial cell cycle arrest and participates in contact inhibition:roleofp21Cip1repression.MolCellBiol24:8813–8822
    64. (2004). Oxygen sensing by HIF hydroxylases.
    65. (2007). Oxygen, a source of life and stress.
    66. (2006). Patterns of tumor oxygenation and their influence on the cellular hypoxic response and hypoxia-directed therapies. Drug Resist Updat 9:185–197
    67. (2005). Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results.
    68. (2001). pHi, aerobic glycolysis and vascular endothelial growth factor in tumour growth.
    69. Pisarcik S et al (2006) HIF-1 regulates hypoxic induction of NHE1 expression and alkalinization of intracellular pH in pulmonary arterial myocytes.
    70. (2006). PML inhibits HIF1alpha translation and neoangiogenesis through repression of mTOR.
    71. (2005). Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxyD-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer.
    72. (2005). Quantitative evaluation and modeling of two-dimensional neovascular network complexity: the surface fractal dimension.
    73. (1998). Reduced lysyl oxidase messenger RNA levels in experimental and human prostate cancer.
    74. (2006). Regulation of BNIP3 in normal and cancer cells.
    75. (2006). Regulation of Ecadherin expression by VHL and hypoxia-inducible factor.
    76. (2005). Regulation of phosphoglucose isomerase/autocrine motility factor expression by hypoxia.
    77. (2007). Role of autophagy in cancer.
    78. (2006). Role of tumorassociated macrophages in tumor progression and invasion.
    79. Sataur A et al (2006) Differential regulation of the transcriptional activities of hypoxia-inducible factor 1 alpha (HIF1alpha) and HIF-2alpha in stem cells.
    80. Semenza GL et al (2006) HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia.
    81. (2005). Signalling hypoxia by HIF hydroxylases.
    82. (2005). Signalling via the hypoxia-inducible factor-1alpha requires multiple posttranslational modifications.
    83. Sivridis E et al (2005) Pyruvate dehydrogenase and pyruvate dehydrogenase kinase expression in non small cell lung cancer and tumor-associated stroma.
    84. (2006). Stromal derived factor1 (SDF-1/CXCL12) and CXCR4 in renal cell carcinoma metastasis.
    85. (2003). Structure of human FIH-1 reveals a unique active site pocket and interaction sites for HIF-1 and von Hippel-Lindau.
    86. (2007). Synergistic upregulation of Hexokinase-2, glucose transporters and angiogenic factors in pancreatic cancer cells by glucose deprivation and hypoxia.
    87. (2003). Targeting HIF-1 for cancer therapy.
    88. (2001). Targeting of HIFalpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation.
    89. (2003). The biology of VEGF and its receptors.
    90. (2006). The effect of hyperbaric oxygen therapy on tumour growth in a mouse model of colorectal cancer liver metastases.
    91. (2001). The effects of extracellular pH on immune function.
    92. (2006). The lysyl oxidase LOX is absent in basal and squamous cell carcinomas and its knockdown induces an invading phenotype in a skin equivalent model.
    93. (2006). The oxygen sensor factor-inhibiting hypoxia-inducible factor-1 controls expression of distinct genes through the bifunctional transcriptional character of hypoxia-inducible factor-1alpha.
    94. (2006). The plasma membrane lactate transporter MCT4, but not MCT1, is upregulated by hypoxia through a HIF-1alpha-dependent mechanism.
    95. (2004). The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress.
    96. (1996). The whole structure of the 13-subunit oxidized cytochrome c oxidase at 2.8 A.
    97. (2007). Tie2-expressing monocytes: regulation of tumor angiogenesis and therapeutic implications.
    98. (2006). Tirapazamine plus cisplatin in advanced or recurrent carcinoma of the uterine cervix: a Southwest Oncology Group study.
    99. (2002). Tirapazamine: a hypoxia-activated topoisomerase II poison.
    100. (2001). Transcription factor HIF-1 is a necessary mediator of the pasteur effect in mammalian cells.
    101. (2005). Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1.
    102. (2001). Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects.
    103. (2003). VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia.
    104. (2007). VHL promotes E2 box-dependent E-cadherin transcription by HIF-mediated regulation of SIP1 and snail.
    105. Voelkl S et al (2007) Inhibitory effect of tumor cell-derived lactic acid on human T cells.
    106. Vumbaca F et al (2006) Hypoxia stimulates breast carcinoma cell invasion through MT1-MMP and MMP-2 activation.
    107. (2004). Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4:891–899
    108. (2002). ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.